Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Fernández Rodríguez, M. Concepción
• dc.contributor.author Rodríguez-Sevilla, Juan José
• dc.contributor.author Fernández-Ibarrondo, Lierni
• dc.contributor.author Sánchez González, Blanca
• dc.contributor.author Gibert Fernandez, Joan, 1988-
• dc.contributor.author Bento, Leyre
• dc.contributor.author García, Juan Fernando
• dc.contributor.author Sancho, Juan Manuel
• dc.contributor.author Díez-Feijóo, Ramón
• dc.contributor.author Camacho Díaz, Laura
• dc.contributor.author García-Retortillo, Montserrat
• dc.contributor.author Gimeno Vázquez, Eva
• dc.contributor.author Colomo Saperas, Luis Alberto
• dc.contributor.author Gutierrez, Antonio
• dc.contributor.author Bellosillo Paricio, Beatriz
• dc.contributor.author Salar Silvestre, Antonio
• dc.date.accessioned 2022-05-23T06:31:12Z
• dc.date.available 2022-05-23T06:31:12Z
• dc.date.issued 2022
• dc.description.abstract Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. Anti-HBcore+ (anti-HBc+) cases presented with older age at diagnosis than anti-HBc- cases (68.1 vs 57.2 years; P = .007) and higher β2-microglobulin (56.3% vs 28.9%; P = .04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and/or maintenance. Remarkably, anti-HBc+ patients had significantly lower 10-year progression-free survival (PFS; 12.9% vs 58.3%; P < .0001) and overall survival (OS; 22.0% vs 86.2%; P < .0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc+ cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.
• dc.format.mimetype application/pdf
• dc.identifier.citation Fernández-Rodríguez C, Rodríguez-Sevilla JJ, Fernández-Ibarrondo L, Sánchez-González B, Gibert J, Bento L, et al. Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. Blood Adv. 2022 Jan 11; 6(1): 82-6. DOI: 10.1182/bloodadvances.2021005316
• dc.identifier.doi http://dx.doi.org/10.1182/bloodadvances.2021005316
• dc.identifier.issn 2473-9529
• dc.identifier.uri http://hdl.handle.net/10230/53193
• dc.language.iso eng
• dc.publisher American Society of Hematology
• dc.rights Copyright © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), http://creativecommons.org/licenses/by-nc-nd/4.0/ permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.other Hepatitis B
• dc.subject.other Limfomes
• dc.subject.other Quimioteràpia combinada
• dc.title Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion